InnoCare Pharma Ltd.SSE: 688428

Announcement on Convening the Q3 2024 Performance Briefing

Nov 5, 2024 · Issued by InnoCare Pharma Ltd. via Shanghai Stock Exchange

Filed with SSE · Nov 5, 2024

On 6ix: 6ix.com/news/announcement-on-convening-the-q3-2024-performance-briefing-318

Announcement on Convening the Q3 2024 Performance Briefing

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

6ix hasn’t read this filing yet.

InnoCare Pharma Ltd. on 6ix

Earlier from InnoCare Pharma

Announcement on Voluntary Disclosure of Phase II Clinical Trial Result of ICP-488Oct 10, 2024
Announcement on the Resignation of Non-executive Directors and Independent Non-executive Directors and the Change of Members of Special Committees of the Board of DirectorsSep 26, 2024
Announcement on Change of Sponsor Representative for Continuous SupervisionSep 21, 2024
Announcement on Listing and Circulation of Initial Public Offering of Strategic Placement Restricted SharesSep 11, 2024
Announcement on Voluntary Disclosure of Clinical Trial Progress of AobrutinibSep 9, 2024

Later from InnoCare Pharma

The Q3 2024 ReportNov 12, 2024
Summary Announcement on the 2024 STAR Market Restricted Stock Incentive Plan (Draft)Nov 27, 2024
Notice on Convening the 1st Extraordinary General Meeting (Shareholders' Special Meeting) in 2024Nov 29, 2024
Notice on the Review Opinions and Remarks on Publicity of Lis of Incentive Recipients List for the Initial Grant of the 2024 SSE STAR Market Restricted Stock Incentive PlanDec 10, 2024
Announcement on the First Granting of Restricted Stocks to Incentive ObjectsDec 18, 2024

All InnoCare Pharma news releases

Follow InnoCare Pharma into a list and get an email when it puts out news.

Follow InnoCare Pharma